Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis

被引:0
|
作者
Gualtierotti, R. [1 ,2 ]
Ingegnoli, F. [1 ,2 ]
Two, R. [3 ]
Meroni, P. L. [1 ,2 ]
Khanna, D. [4 ]
机构
[1] G Pini Orthoped Inst, Div Rheumatol, I-20122 Milan, Italy
[2] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[3] PharmaQuest Ltd, Banbury, England
[4] Univ Michigan, Ann Arbor, MI 48109 USA
关键词
systemic sclerosis; scleroderma; gastrointestinal tract; health-related quality of life; gastroesophageal reflux; diarrhoea; EQ-5D; SF-36; UCLA-GIT; 2.0; questionnaire; QUALITY-OF-LIFE; FUNCTIONAL STATUS; HEALTH; MANIFESTATIONS; CLASSIFICATION; CONSENSUS; OUTCOMES;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To test the acceptability, feasibility, reliability and validity of the Italian translated version of the UCLA Scleroderma Clinical Trial Consortium GIT (UCLA-SCTC GIT) 2.0. Gastrointestinal tract (GIT) involvement is frequent in systemic sclerosis (SSc). The UCLA-SCTC GIT 2.0 is a validated instrument for measuring the presence and impact of GIT symptoms in SSc patients. Methods. Acceptability and feasibility of the questionnaire were evaluated based on the input from the patients. Internal consistency was evaluated by Cronbach's alpha. External consistency was measured by comparing with the Short Form (SF)-36 and EQ-5D by Spearman's rho, meaningful if >= 0.30. Results. Sixty-two consecutive SSc patients (mean age 60.6) were recruited, 88.5% were female. The UCLA-SCTC GIT 2.0 was well accepted. Percentage of missing data in UCLA-SCTC GIT total score was 2 %. Internal consistency was acceptable (alpha >= 70) for all domains. Cronbach's alpha was >= 0.70 for all domains. UCLA-SCTC GIT 2.0 discriminated between patients with or without gastroesophageal reflux disease whether diagnosed clinically or by objective testing (p<0.01 for both). UCLA-SCTC GIT emotional well-being was correlated with the conceptually equivalent SF-36 mental health domains (correlation coefficient >0.35) and with the EQ-5D usual activities domain (0.38), thus reflecting the impact on everyday activities. The distention/bloating domain strongly correlated with the EQ-5D anxiety/depression domain (0.51) and reflux domain with role emotional of SF-36 (0.44). Conclusion. This is the first validation study of the Italian version of UCLA-SCTC GIT 2.0. Our data support its feasibility, reliability, and validity in Italian SSc patients.
引用
收藏
页码:S55 / S60
页数:6
相关论文
共 35 条
  • [1] A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Gorga, M.
    Mihai, C.
    Soare, A. -M.
    Dobrota, R.
    Gherghe, A. -M.
    Stoica, V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (04) : S61 - S67
  • [2] Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis
    Zekovic, Ana
    Damjanov, Nemanja
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (05) : 735 - 741
  • [3] Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis
    Lee, Tae Hee
    Lee, Joon Seong
    Park, Suyeon
    Lee, Kyung-Ann
    Kim, Hyun-Sook
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (06) : 1504 - +
  • [4] Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Bae, S.
    Allanore, Y.
    Coustet, B.
    Maranian, P.
    Khanna, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : S15 - S21
  • [5] Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis
    Baron, Murray
    Hudson, Marie
    Steele, Russell
    Lo, Ernest
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (09) : 1925 - 1930
  • [6] Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis
    Ana Zekovic
    Nemanja Damjanov
    Rheumatology International, 2017, 37 : 735 - 741
  • [7] Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Ferreira, Pedro L.
    Genrinho, Ines
    Santiago, Tania
    Carones, Adriana
    Mazeda, Carolina
    Barcelos, Anabela
    Beirao, Tiago
    Costa, Flavio
    Santos, Ines
    Couto, Maura
    Rato, Maria
    Terroso, Georgina
    Monteiro, Paulo
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2023, 20 (02)
  • [8] Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
    Ozeri, David
    Peretz, Shani
    Oppenheim, Amit
    Watad, Abdallah
    Lidar, Merav
    Braun-Moscovici, Yolanda
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2023, 8 (01) : 31 - 35
  • [9] Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Khanna, Dinesh
    Furst, Daniel E.
    Maranian, Paul
    Seibold, James R.
    Impens, Ann
    Mayes, Maureen D.
    Clements, Philip J.
    Getzug, Terri
    Hays, Ron D.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (09) : 1920 - 1924
  • [10] Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort
    Low, Andrea Hsiu Ling
    Xin, Xiaohui
    Law, Weng Giap
    Teng, Gim Gee
    Santosa, Amelia
    Lim, Anita
    Chan, Grace
    Ng, Swee Cheng
    Thumboo, Julian
    CLINICAL RHEUMATOLOGY, 2017, 36 (07) : 1643 - 1648